Evaluating ACE Inhibitors and Beta-Blockers to Protect the Heart During Chemotherapy in Children with Acute Leukemia

What this Trial Is About

This research aims to evaluate how cardioprotective medications affect chemotherapy-induced heart damage in children with acute leukemia. The study compares two types of heart-protecting drugs, Angiotensin-converting enzyme ACE inhibitors and beta-blockers, to understand their impact on heart function during cancer treatment. The study focuses on children aged 2 to 18 years and measures heart health using echocardiography. Participants receive either ACE inhibitors or beta-blockers orally, dosed by caregivers or nurses. ACE inhibitors are given at 0.3 mg per kilogram every 8 hours, while beta-blockers are administered at 0.05 mg per kilogram every 12 hours. The treatment is monitored from the start until the end of the chemotherapy induction phase, which lasts 42 days. During the study, childrens heart function is assessed using 2D echocardiography to measure left ventricular ejection fraction LVEF at the beginning and end of the induction phase. Researchers track changes in heart performance to determine how well each medication protects the heart from chemotherapy effects. The total participation period covers these 42 days, with close monitoring of heart health and medication adherence.

Cardioprotection on Chemotherapy-Induced Cardiotoxicity